![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: The myeloproliferative neoplasm, polycythemia vera (PV) significantly impacts the quality of life of afflicted patients. The traditional therapies of phlebotomy, aspirin and cytoreductive medicines center on decreasing the risk of vascular events, but can be inadequate to improve symptom burden. Over time, these therapies may become ineffective or patients may develop intolerances providing a need for more therapeutic options.
Areas covered: Recently, the randomized Phase III RESPONSE trial has demonstrated the ability to improve hematocrit control, reduce splenomegaly and improve symptoms in patients with PV. This has led to the US FDA and the European Commission approval of ruxolitinib for patients with PV who have an inadequate response or intolerance to hydroxyurea (HU). The RELIEF trial recently showed a trend for improved symptom control when ruxolitinib replaced HU in patients attaining good disease control, but inadequate symptom control on HU.
Expert opinion: Ruxolitinib offers another option for therapy in PV with efficacy in hematocrit control, reducing splenomegaly and symptom burden. Future goals include knowing at what juncture in PV should Janus kinase 2 inhibitors be introduced in PV.
Declaration of interest
RA Mesa is a consultant for Novartis and has received research funding from Incyte, Gilead, CTI BioPharma and Promedior. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.